Overview

Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).
Phase:
Phase 3
Details
Lead Sponsor:
Sumitomo Dainippon Pharma Co., Ltd.
Treatments:
Amrubicin
Docetaxel